Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know

Shares of Royalty Pharma (RPRX) have gained 23.4% over the past four weeks to close the last trading session at $30.75, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$40.33 indicates a potential upside of 31.2%.The average comprises six short-term price targets ranging from a low of $28 to a high of$51, with a standard deviation of $7.39. While the lowest estimate indicates a ...